CO4810339A1 - Nuevas estructuras artificiales de proteinas de fusion y metodo de preparacion - Google Patents

Nuevas estructuras artificiales de proteinas de fusion y metodo de preparacion

Info

Publication number
CO4810339A1
CO4810339A1 CO98056054A CO98056054A CO4810339A1 CO 4810339 A1 CO4810339 A1 CO 4810339A1 CO 98056054 A CO98056054 A CO 98056054A CO 98056054 A CO98056054 A CO 98056054A CO 4810339 A1 CO4810339 A1 CO 4810339A1
Authority
CO
Colombia
Prior art keywords
preparation
derivative
fusion proteins
protein
artificial structures
Prior art date
Application number
CO98056054A
Other languages
English (en)
Inventor
Claudine Bruck
Martine Georges Marchand
Stephane Andre Godart
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10819735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO4810339(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of CO4810339A1 publication Critical patent/CO4810339A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Una proteína de fusión caracterizada por comprender: (a) una proteína Tat de VIH o su derivado que puede enlazarse a una secuencia diferente en la fusión, o una proteína Nef de VIH o su derivado; o (b) una proteína Nef de VIH o su derivado enlazada ya sea a una secuencia diferente en la fusión o a una proteína Tat de VIH o su derivado; o (c) una proteína Nef de VIH o su derivado, que puede enlazarse a una proteína Tat de VIH o su derivado y a una secuencia diferente en la fusión.
CO98056054A 1997-09-26 1998-09-25 Nuevas estructuras artificiales de proteinas de fusion y metodo de preparacion CO4810339A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9720585.0A GB9720585D0 (en) 1997-09-26 1997-09-26 Vaccine

Publications (1)

Publication Number Publication Date
CO4810339A1 true CO4810339A1 (es) 1999-06-30

Family

ID=10819735

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98056054A CO4810339A1 (es) 1997-09-26 1998-09-25 Nuevas estructuras artificiales de proteinas de fusion y metodo de preparacion

Country Status (28)

Country Link
EP (1) EP1015596B2 (es)
JP (2) JP2001518300A (es)
KR (1) KR100554487B1 (es)
CN (1) CN1188519C (es)
AR (2) AR017147A1 (es)
AT (1) ATE338128T1 (es)
AU (1) AU746564B2 (es)
BR (1) BR9812547A (es)
CA (1) CA2305013C (es)
CO (1) CO4810339A1 (es)
CZ (1) CZ302878B6 (es)
DE (1) DE69835756T3 (es)
DK (1) DK1015596T4 (es)
ES (1) ES2272012T5 (es)
GB (1) GB9720585D0 (es)
HK (1) HK1030431A1 (es)
HU (1) HUP0004896A3 (es)
IL (1) IL135102A0 (es)
NO (2) NO328824B1 (es)
NZ (1) NZ503482A (es)
PL (1) PL195243B1 (es)
PT (1) PT1015596E (es)
SA (1) SA98190877B1 (es)
SI (1) SI1015596T2 (es)
TR (1) TR200000864T2 (es)
TW (1) TW499436B (es)
WO (1) WO1999016884A1 (es)
ZA (1) ZA988789B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
AU3158900A (en) * 1999-02-25 2000-09-14 Smithkline Beecham Biologicals (Sa) Immunogens comprising a peptide and a carrier derived from h.influenzae protein
WO2000061617A2 (en) * 1999-04-12 2000-10-19 Modex Therapeutiques, S.A. Transiently immortalized cells for use in gene therapy
DE60023300T2 (de) * 1999-06-29 2006-07-06 Glaxosmithkline Biologicals S.A. Verwendung von cpg als adjuvans für hivimpstoff
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
CZ20022643A3 (cs) * 2000-01-31 2003-02-12 Smithkline Beecham Biologicals S. A. Farmaceutický prostředek
US6472176B2 (en) 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
EP1279404A1 (en) * 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
GB0118367D0 (en) * 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
EP1944043A1 (en) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
BR0214350A (pt) 2001-11-21 2005-05-10 Univ Pennsylvania Sequências de ácido nucleico e aminoácido de adenovìrus de sìmio, vetores contendo as mesmas e métodos de uso
KR100466382B1 (ko) * 2002-01-08 2005-01-14 주식회사 엘지생명과학 인간 면역 결핍 바이러스-1, -2 타입의 단백질이 융합된 재조합 콤보 단백질, 이의 생산방법, 이를 포함하는 벡터, 형질전환된 대장균 및 진단키트
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
KR101196178B1 (ko) 2002-05-16 2012-11-01 버베리안 노딕 에이/에스 Ｈｉｖ 조절/부속 단백질의 융합 단백질
GB0225788D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US20050208482A1 (en) 2004-03-16 2005-09-22 Cohen David I Tat-based immunomodulatory compositions and methods for their discovery and use
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
GB0507003D0 (en) * 2005-04-06 2005-05-11 Molmed Spa Therapeutic
AU2006304392B2 (en) 2005-10-18 2014-05-01 National Jewish Health Conditionally immortalized long-term stem cells and methods of making and using such cells
CA2706258C (en) 2007-11-28 2017-06-06 The Trustees Of The University Of Pennsylvania Simian subfamily e adenoviruses sadv-39, -25.2, -26, -30, -37, and -38 and uses thereof
EP2463362B1 (en) 2007-11-28 2017-11-08 The Trustees Of The University Of Pennsylvania Simian subfamily c adenovirus SAdv-31 and uses thereof
JP5661476B2 (ja) 2008-03-04 2015-01-28 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア サルアデノウイルスＳＡｄＶ−３６、−４２．１、−４２．２および−４４ならびにそれらの用途
AU2009246876B2 (en) 2008-05-16 2015-04-02 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
DK2313496T3 (en) 2008-07-21 2014-12-15 Taiga Biotechnologies Inc Anukleære differentiated cells, and method for preparation thereof
AU2009285547B2 (en) 2008-08-28 2012-05-31 Taiga Biotechnologies, Inc. Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC
EP2774985B1 (en) 2008-10-31 2016-12-14 The Trustees Of The University Of Pennsylvania Simian adenovirus SAdV-43 and uses thereof
CN102405057B (zh) 2009-03-23 2016-05-25 那尼尔科斯治疗公司 用免疫刺激性Hiv Tat衍生物多肽治疗癌症
WO2010138675A1 (en) 2009-05-29 2010-12-02 The Trustees Of The University Of Pennsylvania Simian adenovirus 41 and uses thereof
AU2011332025B2 (en) 2010-11-23 2015-06-25 The Trustees Of The University Of Pennsylvania Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof
US9110059B2 (en) * 2011-03-15 2015-08-18 Industry-Academic Cooperation Foundation, Yonsei University Bio-pin
CN105473723A (zh) 2012-05-18 2016-04-06 宾夕法尼亚大学托管会 亚家族e猿腺病毒a1302、a1320、a1331和a1337及其用途
WO2014012090A1 (en) * 2012-07-13 2014-01-16 The Broad Institute, Inc. Molecular sleds comprising a positively-charged amino acid sequence and a molecular cargo and uses thereof
CA2879667C (en) 2012-07-20 2021-11-16 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment comprising a myc polypeptide
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US9663556B2 (en) 2013-10-04 2017-05-30 Pin Pharma, Inc. Treatment of cancers with immunostimulatory HIV tat derivative polypeptides
DK3142750T3 (da) 2014-05-13 2020-09-14 Univ Pennsylvania Sammensætninger omfattende aav, som udtrykker dobbelt-antistofkonstrukter og anvendelser deraf
CN107708671B (zh) * 2015-04-16 2020-12-04 纽约州立大学研究基金会 包含钴卟啉-磷脂缀合物和聚组氨酸标签的纳米结构
US11207421B2 (en) 2015-04-16 2021-12-28 The Research Foundation For The State University Of New York Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags
EP3548425B1 (en) 2016-12-02 2023-03-29 Taiga Biotechnologies, Inc. Nanoparticle formulations
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
KR20240011714A (ko) 2021-04-27 2024-01-26 제너레이션 바이오 컴퍼니 치료용 항체를 발현하는 비바이러스성 dna 벡터 및 이의 용도
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9003010D0 (en) * 1990-02-09 1990-04-04 Glaxo Group Ltd Gene expression in yeast cells
AU681572B2 (en) * 1991-10-21 1997-09-04 Med Immune, Inc. Bacterial expression vectors containing DNA encoding secretion signals of lipoproteins
NZ255831A (en) * 1992-08-21 1997-04-24 Biogen Inc Fusion proteins comprising biologically active cargo moiety and transport peptides from the hiv tat protein, their preparation and use
ATE302854T1 (de) * 1993-01-26 2005-09-15 Univ Pennsylvania Zusammensetzungen und verfahren zur verabreichung von genetischem material
JPH11501310A (ja) * 1995-03-08 1999-02-02 ネオバック レトロウイルスの調節タンパク質から誘導された無毒の免疫原、抗体、製造方法およびそれらを含んでなる医薬組成物
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine

Also Published As

Publication number Publication date
NO20001508L (no) 2000-05-18
SI1015596T2 (sl) 2010-07-30
EP1015596B2 (en) 2010-04-14
NZ503482A (en) 2001-09-28
CZ302878B6 (cs) 2012-01-04
PL339432A1 (en) 2000-12-18
NO20001508D0 (no) 2000-03-23
PT1015596E (pt) 2006-12-29
DK1015596T3 (da) 2007-01-02
NO328824B1 (no) 2010-05-25
AR017147A1 (es) 2001-08-22
JP2009213492A (ja) 2009-09-24
TW499436B (en) 2002-08-21
HK1030431A1 (en) 2001-05-04
ATE338128T1 (de) 2006-09-15
TR200000864T2 (tr) 2000-08-21
DE69835756D1 (de) 2006-10-12
CZ20001091A3 (cs) 2000-09-13
IL135102A0 (en) 2001-05-20
SI1015596T1 (sl) 2007-02-28
CA2305013C (en) 2008-04-08
BR9812547A (pt) 2000-07-25
HUP0004896A3 (en) 2003-05-28
KR100554487B1 (ko) 2006-03-03
DK1015596T4 (da) 2010-07-12
KR20010024287A (ko) 2001-03-26
AU1025599A (en) 1999-04-23
AU746564B2 (en) 2002-05-02
CN1279718A (zh) 2001-01-10
EP1015596A1 (en) 2000-07-05
GB9720585D0 (en) 1997-11-26
ZA988789B (en) 2000-03-29
CA2305013A1 (en) 1999-04-08
ES2272012T3 (es) 2007-04-16
EP1015596B1 (en) 2006-08-30
WO1999016884A1 (en) 1999-04-08
DE69835756T3 (de) 2010-09-30
SA98190877B1 (ar) 2006-09-10
JP2001518300A (ja) 2001-10-16
ES2272012T5 (es) 2010-07-06
CN1188519C (zh) 2005-02-09
AR080331A2 (es) 2012-03-28
HUP0004896A1 (hu) 2001-04-28
NO20076467L (no) 2000-05-18
PL195243B1 (pl) 2007-08-31
DE69835756T2 (de) 2007-09-13

Similar Documents

Publication Publication Date Title
CO4810339A1 (es) Nuevas estructuras artificiales de proteinas de fusion y metodo de preparacion
DK0527760T3 (da) Fremgangsmåder og præparater til vaccination mod HIV
EA199800946A1 (ru) Концентрированный препарат антител
ATE158415T1 (de) Kationisierte antikörper gegen intrazelluläre eiweisse
DK1088084T3 (da) Erythropoietin analog-humant serumalbumin fusionsprotein
SE9301270D0 (sv) Biosensor
DE69021002T2 (de) Schimärische Hepadnavirus-Kernantigenproteine.
AR017167A2 (es) Metodo de fabricar un injerto bifurcado a partir de dos laminas
DE60037450D1 (de) Funf-helix protein
BR0210598A (pt) Complexo solúvel que compreende uma glicoproteìna retroviral de superfìcie
AR001686A1 (es) Una composición vacuna un proceso para prepararla y su uso para la fabricación de una vacuna
DK1159298T3 (da) HIV-peptider, antigener og vaccinekompositioner
DE69021462D1 (de) Peptidyl prolyl-cis, trans-Isomerase.
KR910003095A (ko) 사람의 단백질 c변이체 및 이의 제조방법
MY131433A (en) Novel metazoan parasite antigens having pepstatin binding activity and their use in vaccines
NO932823L (no) Bicyklopolyazamakrocyklofosfonsyrer, deres komplekser og konjugater, for anvendelse som kontrastmidler og fremgangsmåter for deres fremstilling
DK1208213T3 (da) Fremgangsmåde til fremstilling af proteiner i værtsceller under anvendelse af chaperoniner
ATE307201T1 (de) Srcr domäne-enthaltendes protein
ES2196802T3 (es) Lactatos de citronelilo y/o de dihidrocitronelilo, su preparacion y su utilizacion.
ES2177721T3 (es) Gonadotropinas con puentes disulforono nativos.
ES2139292T3 (es) Metodo y estuche (kit) para purificar acidos nucleicos.
ECSP982804A (es) Beta- lipotropina y usos de la misma
ES2009280A6 (es) Un metodo para detectar anticuerpos al virus hiv-1 en una muestra.
IT8821137A0 (it) Fosfatidilcoline idrosolubili, procedimento per la loro preparazione e composizioni farmaceutiche che le contengono.